SMMT 📈 Summit Therapeutics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86627T1088
SMMT: Antibiotics, Bispecific Antibody, Immunotherapy
Summit Therapeutics PLC, listed on the NASDAQ under the ticker symbol SMMT, operates as a biopharmaceutical entity with a multifaceted approach to developing medicinal therapies. The company's primary focus areas include the discovery, development, and subsequent commercialization of novel treatments that cater to the needs of patients, physicians, caregivers, and the broader societal landscape, primarily within the United States and the United Kingdom. This approach underscores the company's commitment to creating therapies that are not only effective but also considerate of the overall healthcare ecosystem.
The company's pipeline is highlighted by its lead development candidate, Ivonescimab, a bispecific antibody designed for immunotherapy. Ivonescimab works through the blockade of PD-1, combined with anti-angiogenesis, representing a dual-pronged approach to treating diseases. Additionally, Summit Therapeutics has a robust anti-infectives portfolio, with SMT-738 being a notable example. SMT-738 belongs to a novel class of precision antibiotics aimed at combating multidrug-resistant infections, particularly those caused by carbapenem-resistant Enterobacteriaceae. This is a critical area of focus given the rising global concern over antibiotic resistance.
Strategic collaborations are a key component of Summit Therapeutics' business strategy. The company has entered into a collaboration and license agreement with Akeso, Inc., and its affiliates, aimed at the development and commercialization of Ivonescimab. Furthermore, it has established a strategic collaboration with The University of Texas MD Anderson Cancer Center. This partnership is designed to accelerate the development of Ivonescimab, leveraging the expertise and resources of one of the world's premier cancer research and treatment institutions. Such collaborations not only enhance the company's capabilities but also underscore its commitment to advancing medical science through cooperative efforts.
Founded in 2003, Summit Therapeutics PLC is headquartered in Miami, Florida, and is publicly traded. The company's common stock is listed under the ISIN US86627T1088 and is classified under the GICS Sub Industry of Biotechnology. This classification reflects the company's core business activities, which are centered on the research, development, and marketing of biotechnological products and services. For more information, the company can be visited online at https://www.summittxinc.com, providing access to detailed information about its mission, products, and strategic initiatives.
Additional Sources for SMMT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SMMT Stock Overview
Market Cap in USD | 13,776m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2015-03-05 |
SMMT Stock Ratings
Growth 5y | 59.4% |
Fundamental | - |
Dividend | - |
Rel. Strength Industry | 41721 |
Analysts | 4.2/5 |
Fair Price Momentum | 19.74 USD |
Fair Price DCF | - |
SMMT Dividends
No Dividends PaidSMMT Growth Ratios
Growth Correlation 3m | -71.1% |
Growth Correlation 12m | 87.5% |
Growth Correlation 5y | 11.8% |
CAGR 5y | 67.14% |
CAGR/Mean DD 5y | 1.27 |
Sharpe Ratio 12m | 1.32 |
Alpha | 508.77 |
Beta | 0.58 |
Volatility | 93.05% |
Current Volume | 3180.3k |
Average Volume 20d | 2195.4k |
As of January 10, 2025, the stock is trading at USD 18.82 with a total of 3,180,300 shares traded.
Over the past week, the price has changed by +2.56%, over one month by +0.86%, over three months by -0.42% and over the past year by +515.03%.
Partly, yes. Based on ValueRay Analyses, Summit Therapeutics (NASDAQ:SMMT) is currently (January 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 59.39 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SMMT as of January 2025 is 19.74. This means that SMMT is currently overvalued and has a potential downside of 4.89%.
Summit Therapeutics has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy SMMT.
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SMMT Summit Therapeutics will be worth about 21.7 in January 2026. The stock is currently trading at 18.82. This means that the stock has a potential upside of +15.09%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 33 | 75.4% |
Analysts Target Price | 5 | -73.4% |
ValueRay Target Price | 21.7 | 15.1% |